|
|
|
| Clinical effect of recombinant human erythropoietin combined with gangliosides for neonatal hypoxic-ischemic encephalopathy |
| ZHU Min SU Caiyun CHEN Qiaoling |
| Department of Pediatrics, Huaibei Miner General Hospital, Anhui Province, Huaibei 235000, China |
|
|
|
Abstract Objective To study the clinical effect of recombinant human erythropoietin (EPO) combined with gangliosides on neonatal hypoxic-ischemic encephalopathy (HIE). Methods A total of 80 cases of children with HIE were selected and divided into the control group (40 cases) and the study group (40 cases) in Huaibei Miner General Hospital from January 2016 to June 2017 according to the treatment. The control group was treated with Monosialoteterahexosyl ganglioside (GM-1). the study group was treated with GM-1 and recombinant human EPO, and the treatment lasted for 10-14 day. The NBNA scale was used to evaluate the neurobehavior on the 7th, 14th, and 28th day after birth. The CDCC and Gesell scales were used to evaluate the intellectual development and developmental quotients of the two groups at 3 months and 6 months of age, respectively, and the therapeutic efficacy and prognosis of the two groups were evaluated. Results There was no significant difference in NBNA scores between the two groups 7 d after birth (P > 0.05). The NBNA scores of the study group were significantly higher on the 14th and 28th day after birth than in the control group (P < 0.05). MDI, PDI scores and Gesell scores at 6 months of age in both groups were significantly higher than those at 3 months of age (P < 0.05). The MDI, PDI scores and Gesell scores of the study group at 3 months and 6 months of age were significantly higher than those of the control group (P < 0.05). The total effective rate in the study group was 92.50%, which was significantly higher than the 75.00% in the control group (P < 0.05). There was no significant difference in sequelae and prognosis between the two groups (P > 0.05). Conclusion The combination therapy of GM-1 and recombinant human EPO can significantly improve the neurobehavioral and central nervous system function in children with HIE. The treatment method has good clinical efficacy, high safety, and has great clinical application value.
|
|
|
|
|
|
[1] Gopagondanahalli KR，Li J，Fahey MC，et al. Preterm hypoxic-ischemic encephalopathy [J]. Front Pediatr，2016， 10（20）：114.
[2] 黄维清，彭小明，颜卫群，等.新生儿缺氧缺血性脑病发病及预后影响因素分析[J].人民军医，2016，59（2）：142-144.
[3] 王显旿.神经节苷脂对缺氧缺血性脑病新生儿神经功能的影响[J].中外医学研究，2017，15（14）：123-125.
[4] 朱静，郭爱丽，张楠，等.促红细胞生成素治疗新生儿缺氧缺血性脑病的疗效观察[J].山东大学学报：医学版，2016，54（4）：60-63.
[5] 中华医学会儿科学分会新生儿学组.新生儿缺氧缺血性脑病诊断标准[J].中华儿科杂志，2005，43（8）：584-584.
[6] 邢珊，刘俐，李改莲，等.NBNA评分在评价早产儿脑发育、脑损伤及预后中的应用[J].中国儿童保健杂志，2016， 24（2）：191-194.
[7] Yu TY，Chen KL，Chou W，et al. Intelligence quotient discrepancy indicates levels of motor competence in preschool children at risk for developmental delays [J]. Neuropsychiatr Dis Treat，2016，12（1）：501-510.
[8] 宋彩虹，刘俐，张明，等.MRI结合Gesell测试对足月新生儿HIE预后判断的研究[J].中国妇幼健康研究，2016， 27（5）：564-567.
[9] 卫生部新生儿疾病重点实验室.足月儿缺氧缺血性脑病循证治疗指南（2011-标准版）[J].中国循证儿科杂志，2011， 6（5）：327-335.
[10] Winerdal M，Winerdal ME，Wang YQ，et al. Adenosine A 1 receptors contribute to immune regulation after neonatal hypoxic ischemic brain injury [J]. Purinergic Signal，2016，12（1）：89-101.
[11] 包克珍，黄勇，胡晓泽，等.新生儿缺氧缺血性脑病危险因素及预后分析[J].中国妇幼保健，2016，31（5）：971-973.
[12] 钱丹，姜勇超，QianDan，等.促红细胞生成素配合单唾液酸四己糖神经节苷脂治疗新生儿缺氧缺血性脑病效果分析[J].中国综合临床，2016，32（3）：272-275.
[13] 李里，邓映英，欧海娟.神经节苷脂在新生儿缺血缺氧性脑病治疗中的应用[J].中国医学创新，2015，12（12）：65-67.
[14] 石境懿，夏利，张衡，等.rhu-EPO辅助治疗对新生儿缺氧缺血性脑病氧化应激损伤及Caspase-3、ACTA水平的影响[J].河北医科大学学报，2017，38（11）：1295-1299.
[15] 蒋琦，赵子充，林梅芳.高胆红素血症新生儿行为神经测定的临床研究[J].现代实用医学，2016，28（11）：1429-1430.
[16] 李光忠.早期智力干预联合神经节苷脂治疗新生儿缺氧缺血性脑病的效果[J].中国当代医药，2017，24（15）：46-48.
[17] 尉娟娟.早期护理干预对新生儿缺氧缺血性脑病预后的影响[J].中国当代医药，2016，23（3）：182-184.
[18] 王月怡，沈文莉，高彩云，等.振幅整合脑电图在新生儿缺氧缺血性脑病早期诊治及预测预后中的应用价值[J].临床和实验医学杂志，2017，16（12）：1227-1230.
[19] Wu YW，Mathur AM，Chang T，et al. High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy：a phase II trial [J]. Pediatrics，2016，137（6）：e20160191.
[20] 吴文清，何苑棉.单唾液酸神经节苷脂治疗新生儿缺氧缺血性脑病的疗效评价[J].中国实用神经疾病杂志，2016， 19（20）：128-129.
[21] Juul SE，Comstock BA，Heagerty PJ，et al. High-dose erythropoietin for asphyxia and encephalopathy（heal）：a randomized controlled trialaspckground，aims，and study protocol [J]. Neonatology，2018，113（4）：331-338.
[22] 果崇慧，杨青.神经节苷脂治疗新生儿缺氧缺血性脑病对患儿血清炎症相关细胞因子和MMP-9的影响[J].河北医药，2018，40（2）：219-223.
[23] 李红翠，王艳坤，张喜云.重组人促红细胞生成素联合丹参注射液治疗新生儿缺氧缺血性脑病[J].航空航天医学杂志，2015，26（12）：1450-1451.
[24] 杜京辉.重组人促红细胞生成素辅助治疗新生儿缺氧缺血性脑病疗效观察[J].山东医药，2015，55（38）：70-71. |
|
|
|
